Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
163.3 SEK | +3.62% | -0.24% | -16.13% |
25/04 | Vitrolife AB Approves Dividend for the Financial Year 2023 | CI |
18/04 | Nordic Stocks Closed Down Thursday; Arjo Series B Fell Furthest | DJ |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is in a robust financial situation considering its net cash and margin position.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 41.74 and 32.7 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.13% | 2.02B | B- | ||
+0.89% | 12.8B | B+ | ||
-10.29% | 7.61B | B- | ||
+1.78% | 5.41B | B | ||
-1.16% | 4.51B | C | ||
+5.74% | 4.49B | C | ||
-50.70% | 3.3B | D+ | ||
+12.21% | 2.73B | - | - | |
-11.50% | 1.73B | D+ | ||
-5.02% | 1.64B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VITR Stock
- Ratings Vitrolife AB